Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177084 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL16904950 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19522921 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19733545 | 1.00 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL22624856 | 0.99 | FAP (0.40) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL22970116 | 0.97 | MAP1LC3B (0.40) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL17210030 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL24438134 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL21131517 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL16730795 | 0.95 | FAP (0.41) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227310-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| WO-2022268050-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | 荣昌生物制药(烟台)股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3590541-B1 | DRUG-CONJUGATES AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021124210-A1 | TREATMENT WITH SITE SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | PFIZER INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021022678-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | 烟台迈百瑞国际生物医药股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| EP-3520817-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | Concortis Biosystems, Corp (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3498301-A1 | KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-2849790-B1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20160074529-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-03 | — | — | US | disclosed |
| US-7659241-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | GENENTECH, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | STXBP1, WASF2, SDAD1 | FAP 2929/4885MAP1LC3B 1638/4885SIRT2 3288/4885 |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | DNPEP, NPEPPS, PIN1 | FAP 43/4885MAP1LC3B 3598/4885SIRT2 2357/4885 |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | FAP 684/4885MAP1LC3B 2964/4885SIRT2 2772/4885 |
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885MAP1LC3B 1146/4885SIRT2 3623/4885 |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885MAP1LC3B 1146/4885SIRT2 3623/4885 |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885MAP1LC3B 1146/4885SIRT2 3623/4885 |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | MCTS1, CA14, TTL | FAP 887/4885MAP1LC3B 366/4885SIRT2 1635/4885 |
| US-20160074529-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885MAP1LC3B 1146/4885SIRT2 3623/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | FAP 684/4885MAP1LC3B 2964/4885SIRT2 2772/4885 |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | MCTS1, CA14, TTL | FAP 887/4885MAP1LC3B 366/4885SIRT2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.